# P Milestone Roadmap Disposition

- **Status:** Sequence concluded
- **Governing role:** Product authority
- **Completed through:** P16 live-order readiness study
- **Final decision:** P17 blocked and not authorized

## Outcome

P5-P15 delivered a usable deterministic research product with optional model previews, narrow internal-use SEC/Kraken ingestion, personal-server operations, and governed trusted-local extension packs.

P16 completed the live-order readiness study and recorded ADR-0044: NO-GO for real-money order execution. Because P17 required explicit P16 approval, P17 cannot start.

## Milestone sequence

| Milestone | Objective | Status |
|---|---|---|
| P5-P8 | Operator visibility, local OHLCV, deterministic research, backtest-to-paper evidence | Complete |
| P9 | SEC fixture/live preview and FRED terms gate | Complete through PR #52 |
| P10 | Capability-based runtime routing | Complete through PR #53 |
| P11 | Read-only local analyst workspace | Complete through PR #54 |
| P12 | Optional local model-assisted previews | Complete through PR #55 |
| P13 | Evidence-gated SEC/Kraken internal-use production ingestion | Complete through PR #56 |
| P14 | Personal-server scheduling, alerts, backup/restore, packaging, and hardening | Complete through PR #57 |
| P15 | Governed trusted-local runtime extension packs | Complete through PR #58 |
| P16 | Real-money readiness threat model and explicit go/no-go ADR | Complete through PR #59; NO-GO |
| P17 | Controlled real-money pilot | Blocked; not authorized |

## Current capability

OSCA is usable as a local and personal-server market-research, backtesting, paper-evidence, ingestion, model-preview, and extension platform. It is not a broker, investment adviser, or autonomous trading system.

## Safe next phase

Future milestones should focus on product usability and release quality:

1. Integrated first-run onboarding and diagnostics.
2. End-to-end manual acceptance testing on a clean machine.
3. Release packaging and upgrade/rollback rehearsal.
4. Workspace usability, evidence export, and operational visibility.
5. Provider and extension documentation for external contributors.

These improvements must preserve ADR-0044 and may not introduce real-order execution.
